These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 35242380)

  • 41. Correlative analysis of gene mutation and clinical features in patients with non-small cell lung cancer.
    Kuang X; Xiao J; Dai LX; Zhang LH; He BX
    Transl Cancer Res; 2019 Jun; 8(3):736-751. PubMed ID: 35116812
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
    Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
    J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mutational characteristics of bone metastasis of lung cancer.
    Huang X; Shi X; Huang D; Li B; Lin N; Pan W; Yan X; Li H; Hao Q; Ye Z
    Ann Palliat Med; 2021 Aug; 10(8):8818-8826. PubMed ID: 34488370
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Investigation of
    Cao Y; Lan D; Ke X; Zheng W; Zeng J; Niu N; Fu C; Deng W; Jin S
    Heliyon; 2024 Jun; 10(11):e32287. PubMed ID: 38912481
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Genetic Alteration Profiling of Chinese Lung Adenocarcinoma and Its Effect on Targeted Therapy Efficacy.
    Liu J; Xu WY; Ye M; Liu Z; Li C
    Front Oncol; 2021; 11():726547. PubMed ID: 34970478
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic and Immunological Role of FAT Family Genes in Non-Small Cell Lung Cancer.
    Feng Z; Yin Y; Liu B; Zheng Y; Shi D; Zhang H; Qin J
    Cancer Control; 2022; 29():10732748221076682. PubMed ID: 35212236
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations.
    Wang F; Diao XY; Zhang X; Shao Q; Feng YF; An X; Wang HY
    Cancer Commun (Lond); 2019 Mar; 39(1):7. PubMed ID: 30823937
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Decoding tumor mutation burden and driver mutations in early stage lung adenocarcinoma using CT-based radiomics signature.
    Wang X; Kong C; Xu W; Yang S; Shi D; Zhang J; Du M; Wang S; Bai Y; Zhang T; Chen Z; Ma Z; Wang J; Dong G; Sun M; Yin R; Chen F
    Thorac Cancer; 2019 Oct; 10(10):1904-1912. PubMed ID: 31414580
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical and molecular impacts of tumor mutational burden in histological and cytological specimens from cancer patients.
    Li L; Chen C; Liu C; Niu L; Pan C
    Ann Transl Med; 2022 Feb; 10(4):214. PubMed ID: 35280376
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Target-based genomic profiling of ctDNA from Chinese non-small cell lung cancer patients: a result of real-world data.
    Chen H; Wang A; Wang J; He Z; Mao Y; Liu L
    J Cancer Res Clin Oncol; 2020 Jul; 146(7):1867-1876. PubMed ID: 32221744
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hot spot mutations in Finnish non-small cell lung cancers.
    Mäki-Nevala S; Sarhadi VK; Rönty M; Kettunen E; Husgafvel-Pursiainen K; Wolff H; Knuuttila A; Knuutila S
    Lung Cancer; 2016 Sep; 99():102-10. PubMed ID: 27565922
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.
    VanderLaan PA; Rangachari D; Mockus SM; Spotlow V; Reddi HV; Malcolm J; Huberman MS; Joseph LJ; Kobayashi SS; Costa DB
    Lung Cancer; 2017 Apr; 106():17-21. PubMed ID: 28285689
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predictive and Prognostic Potential of TP53 in Patients With Advanced Non-Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial (CTONG 0901).
    Li XM; Li WF; Lin JT; Yan HH; Tu HY; Chen HJ; Wang BC; Wang Z; Zhou Q; Zhang XC; Su J; Chen RL; Wu YL; Yang JJ
    Clin Lung Cancer; 2021 Mar; 22(2):100-109.e3. PubMed ID: 33317922
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical Pathological Characteristics and Prognosis of Multigene Co-Mutations in Elderly Patients With Non-Small Cell Lung Cancer: A Retrospective Analysis.
    Li W; Chang F; Zhang H; Meng F; Ke Z; Zhang Y
    Clin Med Insights Oncol; 2023; 17():11795549231211505. PubMed ID: 38033742
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Co-occurring genetic alterations predict distant metastasis and poor efficacy of first-line EGFR-TKIs in EGFR-mutant NSCLC.
    Deng LL; Gao G; Deng HB; Wang F; Wang ZH; Yang Y
    J Cancer Res Clin Oncol; 2019 Oct; 145(10):2613-2624. PubMed ID: 31463717
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
    Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Coexistence of EGFR, KRAS, BRAF, and PIK3CA Mutations and ALK Rearrangement in a Comprehensive Cohort of 326 Consecutive Spanish Nonsquamous NSCLC Patients.
    Martín Martorell P; Huerta M; Compañ Quilis A; Abellán R; Seda E; Blesa S; Chaves FJ; Dualde Beltrán D; Roselló Keränen S; Franco J; Insa A
    Clin Lung Cancer; 2017 Nov; 18(6):e395-e402. PubMed ID: 28550959
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic effect of coexisting TP53 and ZFHX3 mutations in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Zhang L; Zhang T; Shang B; Li Y; Cao Z; Wang H
    Scand J Immunol; 2021 Sep; 94(3):e13087. PubMed ID: 35226388
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Next-Generation Sequencing in Lung Cancer Patients: A Comparative Approach in NSCLC and SCLC Mutational Landscapes.
    Pop-Bica C; Ciocan CA; Braicu C; Haranguș A; Simon M; Nutu A; Pop LA; Slaby O; Atanasov AG; Pirlog R; Al Hajjar N; Berindan-Neagoe I
    J Pers Med; 2022 Mar; 12(3):. PubMed ID: 35330454
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genomic profiling of non-small cell lung cancer with the rare pulmonary lymphangitic carcinomatosis and clinical outcome of the exploratory anlotinib treatment.
    Dong C; Cheng W; Zhang M; Li S; Zhao L; Chen D; Qin Y; Xiao M; Fang S
    Front Oncol; 2022; 12():992596. PubMed ID: 36324591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.